Original 1972 Nootropic Paper in French: : “VERS UNE PHARMACOLOGIE DE L’ACTIVITÉ INTÉGRATIVE DU CERVEAU: TENTATIVE DU CONCEPT NOOTROPE EN PSYCHOPHARMACOLOGIE” (TOWARDS A PHARMACOLOGY OF INTEGRATIVE BRAIN ACTIVITY: ATTEMPT AT NOOTROPIC CONCEPT IN PSYCHOPHARMACOLOGY)
The pharmacology of the nootropics; new insights and new questions
CDP-choline reduces dopaminergic cell loss induced by MPP(+) and glutamate in primary mesencephalic cell culture.
Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women
Comparative Studies of Noopept and Piracetam in the Treatment of Patients with Mild Cognitive Disorders in Organic Brain Diseases of Vascular and Traumatic Origin
Increase in the Power of Human Memory in Normal Man through the Use of Drugs
NOOTROPIC TREATMENT AND COMBINED THERAPY IN AGE-ASSOCIATED MEMORY IMPAIRMENT
Neuroprotective and Nootropic Drug Noopept Rescues α-Synuclein Amyloid Cytotoxicity
Nootroo™ is a trademark of Nootroo LLC. The Gold Standard In Nootropics™ is trademark of Nootroo LLC. Cognizin® is a registered trademark of KYOWA Kyowa Hakko Bio. None of the statements on the website have been evaluated by the Food and Drug Administration and are not intended as medical advice. This product is not intended to diagnose, treat, cure, or prevent any disease. Nootroo is for adults aged 18 and older. If you are pregnant or undergoing treatment for a medical condition, please consult your physician before taking taking nootropics like Nootroo. Phenylpiracetam and noopept are not vitamins, minerals, amino acids, herbs or other botanical, or dietary substances for use by man to supplement the diet by increasing the total dietary intake.